Overall, these results suggest that ENO2 is a potential prognosis biomarker of ccRCC and could affect the malignant biological behavior of cancer cells, highlighting its value as a potential therapeutic target. This evidence concerns the gene ENO2 and nonpapillary renal cell carcinoma.